Intellia Therape Stock Price, News & Analysis

Intellia Therapeutics (NASDAQ: NTLA) will present its third quarter 2021 financial results and operational highlights on November 4, 2021, at 8 a.m. ET. The call can be accessed via U.S. dial-in at 1-833-316-0545 or international at 1-412-317-5726. It will feature crucial insights on the company's advancements in developing curative CRISPR/Cas9 therapeutics. Additionally, a replay will be available on the company's Investors & Media section after the call.

Intellia Therapeutics (NASDAQ: NTLA) announced that the FDA granted orphan drug designation to NTLA-2001 for treating ATTR amyloidosis. This investigational therapy is the first CRISPR treatment designed for systemic use. NTLA-2001 aims to be a potential single-dose treatment, possibly halting the disease’s complications. Intellia is committed to advancing its genome editing platform, with NTLA-2001 currently in Phase 1 trials. The FDA's designation provides development incentives, echoing a similar approval from the European Commission earlier this year.

Intellia Therapeutics (NASDAQ:NTLA) recently showcased significant preclinical advancements in its CRISPR/Cas9 genome editing platform at the ESGCT Annual Congress. Key highlights included the development of immune-evading allogeneic T cells, effective lipid nanoparticle delivery methods, and successful gene therapy results in non-human primates for treating alpha-1 antitrypsin deficiency (AATD). These findings support the company's strategy to progress its therapeutic candidates, including NTLA-5001 for acute myeloid leukemia, set to initiate clinical trials by year-end.

Intellia and SparingVision have announced a strategic collaboration to utilize Intellia's CRISPR/Cas9 technology for developing ocular therapies targeting three significant diseases. Intellia will grant SparingVision exclusive rights to its technology, receiving a 10% equity stake and potential milestone payments of up to $200 million per product. Additionally, Intellia may secure US commercialization rights for two targets. The collaboration aims to leverage both companies' strengths in genomic medicine and address unmet medical needs in ophthalmology. An investor webcast will provide further details.

Intellia Therapeutics (NASDAQ:NTLA) has presented key findings at the 29th Annual Congress of the European Society of Gene & Cell Therapy. The company showcased its proprietary allogeneic T cell therapy platform designed to address immune rejection in therapeutic candidates for cancer and autoimmune diseases. Significant advancements include a lipid nanoparticle-based CRISPR/Cas9 delivery system and the first reported consecutive in vivo gene insertion and knockout in non-human primates aimed at treating alpha-1 antitrypsin deficiency (AATD). This work positions Intellia at the forefront of genome editing therapeutics.

Intellia Therapeutics has received authorization from New Zealand's MEDSAFE to initiate a Phase 1/2 clinical study for NTLA-2002, a CRISPR/Cas9-based therapeutic aimed at treating hereditary angioedema (HAE). NTLA-2002 is designed to inactivate the KLKB1 gene, potentially providing a one-time treatment to prevent debilitating attacks associated with HAE. Patient enrollment is expected to start by year-end, with further regulatory applications planned globally. The program builds on insights gained from previous trials on NTLA-2001 for ATTR amyloidosis.

Intellia Therapeutics (NASDAQ:NTLA) will present at Chardan’s 5th Annual Genetic Medicines Conference on October 4, 2021, at 10:30 a.m. ET. This clinical-stage genome editing company is focused on developing curative therapeutics using CRISPR/Cas9 technology through in vivo and ex vivo methods. A live webcast of the presentation will be available on their website approximately 15 minutes prior to the start. A replay will be accessible for 14 days following the event.

Intellia Therapeutics (NASDAQ:NTLA) announced the FDA's acceptance of the IND application for NTLA-5001, its first ex vivo CRISPR-engineered therapy targeting Wilms’ Tumor 1 (WT1) for acute myeloid leukemia (AML). This milestone paves the way for a Phase 1/2a clinical study, expected to start patient screening by year-end, focusing on AML patients post-first-line therapy. The therapy aims to improve the five-year survival rate, currently below 30%. The study will involve up to 54 participants across two dosing categories, assessing safety and anti-tumor efficacy.

Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage genome editing company, will participate in two virtual healthcare investor conferences in September 2021. The first will be at the Wells Fargo Healthcare Conference on September 9 at 10:40 am ET, followed by the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 am ET. Live webcasts of the presentations will be available on Intellia's website, with replays accessible for 14 days post-event. Intellia focuses on curative therapeutics powered by CRISPR/Cas9 technology.